Skip to Content

Portrazza Approval History

FDA Approved: Yes (First approved November 24, 2015)
Brand name: Portrazza
Generic name: necitumumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer

Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.

Development History and FDA Approval Process for Portrazza

DateArticle
Nov 24, 2015Approval FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer
Jul  9, 2015Lilly Statement On FDA Advisory Committee Review Of Necitumumab
May 14, 2014Lilly's Necitumumab Improves Overall Survival In Largest Ever Phase III Study

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide